FAMAR Group Announces Acquisition of Sterile Manufacturing Site
FAMAR Group, a leading European pharmaceutical contract development and manufacturing organization (CDMO), is thrilled to announce its latest acquisition of a sterile production facility. This strategic move is a pivotal part of FAMAR's growth journey and underscores its commitment to advancing high-value dosage forms. The new site enhances its capabilities in aseptic and lyophilized fill and finish processes, which are essential for modern pharmaceutical manufacturing.
Significant Investment in the Homburg Facility
The newly acquired facility has undergone substantial modernization, making it a cornerstone of FAMAR's robust international manufacturing network. With this addition, FAMAR will now manage seven production sites across Europe. This expansion greatly boosts the company's ability to offer flexible, high-quality, and scalable production solutions to its growing customer base.
Leadership Insights on the Acquisition
CEO Konstantinos Rengis expressed excitement about this acquisition, stating, "The Homburg site offers world-class sterile infrastructure, newly installed quality control and microbiology laboratories, and a skilled workforce. This investment aligns perfectly with our strategy to expand in differentiated dosage forms while ensuring we provide the highest standards of manufacturing services to our global customers. We welcome the Homburg team into the FAMAR family and are eager to build a promising future together."
Focus on Employee Continuity and Development
As part of this transaction, around 100 employees will transition to FAMAR, ensuring that expertise and knowledge are retained during this change. This site will evolve into a multi-client CDMO platform, positioning FAMAR as a leader in complex and high-value pharmaceutical production.
Support from MiP Pharma's Leadership
Dr. Friedrich Sernetz, CEO of MiP Pharma, expressed confidence in this collaboration, remarking, "Thanks to recent investments, the Homburg facility has transformed into an appealing destination for global pharmaceutical experts. With FAMAR as the new owner, the site stands to grow further, safeguarding jobs and enabling future development."
Partnership with MidEuropa
Moreover, Matthew Strassberg, Partner and Head of Healthcare Sector Practice at MidEuropa, highlighted the strategic importance of this acquisition, stating, "We are delighted to support FAMAR's mission to cater to its international customer base effectively and comprehensively. The acquisition of the Homburg site is a testament to our commitment to FAMAR as it ramps up its expansion into value-added services and formulations."
About FAMAR Group
FAMAR is recognized as a premium European provider of pharmaceutical and cosmetic manufacturing and development services. With a rich legacy of over 75 years, FAMAR excels in producing high-quality dosage forms such as sterile liquids, solids, and semi-solids that add significant value for its clients. Currently operating in various countries, including Spain, Italy, and Greece, FAMAR employs over 1,850 individuals across its six production facilities and two R&D centers, catering to more than 80 international markets with an extensive product range exceeding 1,700 items.
Understanding MiP Pharma Group
MiP Pharma Group specializes in marketing prescription generics, particularly focusing on antibiotics, over-the-counter medicines, and medical devices. Their primary sales strategy targets the hospital sector and specific medical specialties. With a dedicated workforce of over 200 employees and numerous marketing authorizations, MiP Pharma reported sales around 50 million euros in its recent financial year. Since late 2020, MiP Pharma has been backed by capiton AG, a financial investor based in Berlin.
Frequently Asked Questions
What is the significance of FAMAR Group's acquisition?
This acquisition enhances FAMAR's capabilities in sterile manufacturing, reinforcing its position in the pharmaceutical industry.
What changes will occur at the Homburg facility?
The facility will embrace a multi-customer CDMO platform, focusing on complex pharmaceutical manufacturing while ensuring job security for existing employees.
Who is leading FAMAR Group?
Konstantinos Rengis is the CEO, guiding FAMAR in its strategic initiatives and growth plans.
What is the history of FAMAR Group?
FAMAR has a 75-year legacy in pharmaceutical manufacturing, recognized for its quality and innovation in producing various dosage forms.
How many locations does FAMAR operate?
With the acquisition in Homburg, FAMAR will manage a total of seven production facilities across Europe.
